Studying which factors predict outcomes in heart failure with preserved ejection fraction
Follows adults with heart failure with preserved ejection fraction over at least 3 years.
Plain-language title generated from the registry record
Registry title: Predictors of Poor Prognosis in HFpEF
Key facts
- Where
- Moscow, RussiaSee the site
Where in Russia
- Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADEMICIAN E.I.CHAZOV. of the Ministry of Health of the Russian FederationMoscow, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Trial code
- NCT06844032
- Record updated
- 17 April 2026
- Original description
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.Read full original descriptionShow less
Clinical, Hemodynamic and Neurohumoral Predictors of Poor Prognosis in Heart Failure With Preserved Ejection Fraction
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
Inclusion: Signed and data informed consent; New York Heart Association (NYHA) class II-III heart failure; Left ventricular ejection fraction > 50%; Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.
Exclusion: Exacerbation of heart failure less than 3 months prior to study entry; Evidence of myocardial ischemia during stress echocardiography; Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.); Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion; Significant lung disease (severe lung disease requiring home oxygen or chronic oral steroid therapy); Primary pulmonary artery hypertension; Significant left-sided structural valve disease; Non-cardiac conditions that complicate/exclude participation in the study; Anemia (Hb < 100 g/L); Impaired renal function, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (CKD-EPI); Significant lesions of the main coronary arteries.